Tempest Therapeutics Inc
TPSTHealthcare·Biotechnology·USA·Nano·NASD·Nov 13 • 8:12 AM ET
0.40+0.02 (4.44%)
2026-11-13 14:17 CET
Market cap
$7.99M
Revenue, TTM
0.00 USD m
Net income, TTM
-40.47 USD m
Free cash flow, TTM
-20.73 USD m
EPS diluted, TTM
-4.48
Price
TPST against its 20, 50 and 200-day averagesPatternshover a marker to name it
95.9% under the 52-week high of 9.75 on 17 Nov 2025. 52-week low 0.34 on 10 Nov 2026. Last 15 sessions, 66.2% high to low
Volume 0.11× normal · the line is the 50-bar volume average
Setup. RS line 0
CANSLIM 3 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 1 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 3 of 4 — fails: Return on Equity: Over +15%
Quality 0 of 5 — fails: Return on Equity: Over +15%; Current Ratio: Over 1 — not on the tape: Net Profit Margin: High (>20%); Debt/Equity: Low (<0.1); P/E: Under 25
Value 0 of 4 — fails: Return on Equity: Over +15% — not on the tape: P/E: Under 15; P/B: Under 2; Debt/Equity: Low (<0.1)
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 2 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 1 of 4 — fails: Institutional Ownership: Over 30%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200
Profile
TPST52-week range, 1% of the way up
0.349.75
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company's novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.
| Employees | 4 |
|---|---|
| IPO | Nov 12, 2012 |
| Beta | -1.54 |
| ATR, 14d | 0.06 |
| Rel volume | 0.11 |
| Short float | 2.00% |
| Insider own | 39.64% |
| Inst own | 5.39% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | $7.99M |
| Enterprise Value | 14.77M |
| Income | -40.47M |
| Sales | 0.00M |
| Book / share | -0.07 |
| Cash / share | 0.04 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 4 |
| IPO | Nov 12, 2012 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | - |
| Price / book | - |
| Price / cash | 10.25 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | - |
| Quick Ratio | 0.38 |
| Current Ratio | 0.38 |
| Debt / equity | - |
| Long-term debt / equity | - |
| Options and short | No / Yes |
Earnings
| Earnings / share | -4.48 |
|---|---|
| Earnings next year | -0.90 |
| Earnings next quarter | -0.32 |
| Earnings this year | 54.98% |
| Earnings next year | 68.42% |
| Earnings growth, 5 years | - |
| Past earnings growth | 46.00% 76.03% |
| Past sales growth | - - |
| Earnings vs last year | 69.34% |
| Sales vs last year | - |
| Earnings vs last quarter | 83.35% |
| Sales vs last quarter | - |
| Earnings | Aug 13 AMC |
| Surprise | - - |
Ownership
| Insiders own | 39.64% |
|---|---|
| Insider trades | 3.01% |
| Institutions own | 5.39% |
| Institution trades | 14.17% |
| Return on assets | -237.25% |
| Return on equity | -931.14% |
| Return on capital | -780.86% |
| Gross Margin | - |
| Operating margin | - |
| Profit Margin | - |
| 20-day average | -14.98% |
| 50-day average | -41.64% |
| 200-day average | -71.13% |
Technical
| Shares out | 15.98M |
|---|---|
| Shares floating | 12.07M |
| Short / float | 2.00% |
| Short ratio | 0.09 |
| Short interest | 0.24M |
| 52-week high | 9.75 -95.9% |
| 52-week low | 0.34 +18.7% |
| Volatility | 14.75% 10.61% |
| Average range | 0.06 |
| Strength index | 31.09 |
| Market sensitivity | -1.54 |
| Relative volume | 0.11 |
| Avg Volume | 2.54M |
| Volume | 14,304 |
Performance
| Perf Week | 5.02% |
|---|---|
| Perf Month | -37.06% |
| Perf Quarter | -64.63% |
| Perf Half Y | -78.16% |
| Perf YTD | -86.07% |
| Perf Year | -95.49% |
| Perf 3Y | -99.11% |
| Perf 5Y | -99.73% |
| Perf 10Y | -100.00% |
| Recommendation | 1.00 |
| Target Price | 7.00 |
| Prev Close | 0.38 |
| Price | 0.40 |
| Change % | 4.36% |
Analyst ratings
latest 5 of 5| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Jan 22, 2026 | Upgrade | H.C. Wainwright | Neutral → Buy | $11 | +2,652.1% |
| Apr 10, 2025 | Downgrade | Scotiabank | Sector Outperform → Sector Perform | ||
| Apr 10, 2025 | Downgrade | H.C. Wainwright | Buy → Neutral | ||
| Mar 14, 2024 | Initiated | Scotiabank | Sector Outperform | $13 | +3,152.4% |
| Feb 08, 2024 | Initiated | Jefferies | Buy | $15 | +3,652.8% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| TVRD | Tvardi Therapeutics Inc | 14.94M |
| ACTU | Actuate Therapeutics Inc | 16.23M |
| CRDF | Cardiff Oncology Inc | 56.60M |
| IMRX | Immuneering Corp | 240.98M |
| BDTX | Black Diamond Therapeutics Inc | 90.22M |
| HOWL | Werewolf Therapeutics Inc | 49.09M |
| KZIA | Kazia Therapeutics Limited ADR | 79.55M |
| OSTX | OS Therapies Inc | 39.24M |
| ZNTL | Zentalis Pharmaceuticals Inc | 164.18M |
| PRLD | Prelude Therapeutics Inc | 277.69M |
Insider trading
2 filings| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Angel Matthew | CEO and President | Mar 24 '26 | Buy | 2.16 | 231,482 | 500,001 | 231,482 | Jun 23 04:56 PM |
| Angel Matthew | CEO and President | Mar 24 '26 | Buy | 2.16 | 231,482 | 500,001 | 231,482 | Mar 25 05:32 PM |
Held by
AUMNews
latest 14 of 200- Tempest Therapeutics Exercises Option to License Senlang's CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate (GlobeNewswire) +6.09%
- Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise (GlobeNewswire) -6.77%
- Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors (GlobeNewswire) -7.80%
- Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform (GlobeNewswire) +60.18%
- Tempest Therapeutics Announces Up to $7.5 Million Private Placement (GlobeNewswire)
- Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
- Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) -13.25%
- Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T (GlobeNewswire)
- Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026 (GlobeNewswire) +9.13%
- Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors (GlobeNewswire)
- Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds (GlobeNewswire) -11.56%
- Tempest Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +13.59% -12.44%
- Tempest Presents Clinical Update at ISCT 2026 Annual Meeting (GlobeNewswire) -6.05%
- Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting (GlobeNewswire)
Quarterly earnings
2026Q2 EPS -0.340, from -2.070 a year earlier. Sales 0.00, from 0.00 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q2ended 2026-06-30 | 2026-08-13 16:30 | -0.340 | - | -0.340 | 0.00 | - | EPS - · sales - | vs 2025Q2, year-ago quarter · EPS -83.6% · sales - | - | Open -4.27% vs SPY +0.08%. Close -13.25% vs SPY -0.20% |
| 2026Q1ended 2026-03-31 | 2026-05-14 16:30 | -2.530 | -0.280 | -2.534 | 0.00 | 0.00 | EPS +803.6% · sales - | vs 2025Q1, year-ago quarter · EPS -19.9% · sales - | 1 | Open -4.31% vs SPY -0.85%. Close -12.44% vs SPY -1.20% |
| 2025Q4ended 2025-12-31 | 2026-03-30 08:30 | -0.310 | -0.620 | -0.816 | 0.00 | 0.00 | EPS -50.0% · sales - | vs 2024Q4, year-ago quarter · EPS -92.3% · sales - | 1 | Open -2.31% vs SPY +0.95%. Close -12.14% vs SPY -0.33% |
| 2025Q3ended 2025-09-30 | 2025-11-05 08:30 | -0.790 | - | -0.791 | 0.00 | - | EPS - · sales - | vs 2024Q3, year-ago quarter · EPS -85.2% · sales - | - | Open +0.33% vs SPY -0.04%. Close +9.10% vs SPY +0.35% |
| 2025Q2ended 2025-06-30 | 2025-08-11 16:30 | -2.070 | -3.230 | -2.069 | 0.00 | 0.00 | EPS -35.9% · sales - | vs 2024Q2, year-ago quarter · EPS -62.1% · sales - | 1 | Open -3.75% vs SPY +0.37%. Close +9.99% vs SPY +1.06% |
| 2025Q1ended 2025-03-31 | 2025-05-13 16:30 | -3.160 | -3.293 | -3.159 | 0.00 | 0.00 | EPS -4.0% · sales - | vs 2024Q1, year-ago quarter · EPS -32.5% · sales - | 3 EPS · 2 sales | Open -1.91% vs SPY +0.17%. Close -3.53% vs SPY +0.13% |
| 2024Q4ended 2024-12-31 | 2025-03-27 16:30 | -4.030 | -3.274 | -4.084 | 0.00 | 0.00 | EPS +23.1% · sales - | vs 2023Q4, year-ago quarter · EPS -18.4% · sales - | 5 EPS · 4 sales | Open -5.95% vs SPY -0.27%. Close -8.08% vs SPY -2.01% |
| 2024Q3ended 2024-09-30 | 2024-11-12 16:30 | -5.330 | -4.706 | -5.318 | 0.00 | 0.00 | EPS +13.3% · sales - | vs 2023Q3, year-ago quarter · EPS -14.6% · sales - | 5 EPS · 4 sales | Open -13.31% vs SPY +0.08%. Close -10.50% vs SPY +0.05% |
| 2024Q2ended 2024-06-30 | 2024-08-08 16:30 | -5.460 | -5.242 | -5.518 | 0.00 | 0.00 | EPS +4.2% · sales - | vs 2023Q2, year-ago quarter · EPS -22.2% · sales - | 5 EPS · 4 sales | Open +2.99% vs SPY -0.16%. Close -14.18% vs SPY +0.44% |
| 2024Q1ended 2024-03-31 | 2024-05-09 16:30 | -4.680 | -5.234 | -4.621 | 0.00 | 0.00 | EPS -10.6% · sales - | vs 2023Q1, year-ago quarter · EPS -34.5% · sales - | 6 EPS · 4 sales | Open +2.02% vs SPY +0.32%. Close -6.34% vs SPY +0.13% |
| 2023Q4ended 2023-12-31 | 2024-03-19 16:30 | -4.940 | -5.034 | -4.523 | 0.00 | 0.00 | EPS -1.9% · sales - | vs 2022Q4, year-ago quarter · EPS -32.1% · sales - | 6 EPS · 4 sales | Open 0.00% vs SPY +0.01%. Close +0.53% vs SPY +0.92% |
| 2023Q3ended 2023-09-30 | 2023-11-08 16:30 | -6.240 | -7.450 | -6.247 | 0.00 | 0.00 | EPS -16.2% · sales - | vs 2022Q3, year-ago quarter · EPS -27.3% · sales - | 4 EPS · 3 sales | Open +22.34% vs SPY +0.27%. Close +16.31% vs SPY -0.78% |
| 2023Q2ended 2023-06-30 | 2023-08-10 16:30 | -7.020 | -6.727 | -6.989 | 0.00 | 0.00 | EPS +4.3% · sales - | vs 2022Q2, year-ago quarter · EPS -31.6% · sales - | 4 EPS · 3 sales | - |
| 2023Q1ended 2023-03-31 | 2023-05-10 16:30 | -7.150 | -8.353 | -7.213 | 0.00 | 0.00 | EPS -14.4% · sales - | vs 2022Q1, year-ago quarter · EPS -53.4% · sales - | 4 EPS · 3 sales | - |
| 2022Q4ended 2022-12-31 | 2023-03-22 16:30 | -7.280 | -9.884 | -11.251 | 0.00 | 0.00 | EPS -26.3% · sales - | vs 2021Q4, year-ago quarter · EPS -50.1% · sales - | 4 EPS · 3 sales | - |
| 2022Q3ended 2022-09-30 | 2022-11-08 08:30 | -8.580 | -10.433 | -8.530 | 0.00 | 0.00 | EPS -17.8% · sales - | vs 2021Q3, year-ago quarter · EPS -45.5% · sales - | 4 EPS · 3 sales | - |
Annual earnings
2025FY EPS -6.330 missed -6.100, from -19.500 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2029FYestimate | - | -4.230 | - | - | 0.00 | - |
| 2028FYestimate | - | -0.890 | - | - | 4.30 | - |
| 2027FYestimate | - | -0.900 | - | - | 0.00 | - |
| 2026FYestimate | - | -2.850 | - | - | 0.00 | - |
| 2025FY | -6.330 | -6.100 | -6.330 | 0.00 | 0.00 | - |
| 2024FY | -19.500 | -17.495 | -19.496 | 0.00 | 0.00 | - |
| 2023FY | -24.830 | -25.146 | -24.869 | 0.00 | 0.00 | - |
| 2022FY | -40.170 | -42.275 | -40.196 | 0.00 | 0.00 | - |
| 2021FY | -97.110 | -83.373 | -97.070 | 0.00 | 0.00 | - |
| 2020FY | -376.35 | -368.55 | -8,001 | - | - | - |
| 2019FY | -633.75 | -621.51 | -634.05 | 0.00 | 0.00 | - |
| 2018FY | -3,428 | -442.65 | -3,427 | 0.00 | 0.00 | - |
| 2017FY | -4,183 | -4,288 | -941,283 | 0.30 | 0.40 | - |
| 2016FY | -7,488 | -7,313 | -7,488 | 0.65 | 0.66 | - |
| 2015FY | -7,898 | -7,751 | -7,898 | 0.28 | 0.40 | - |
| 2014FY | -6,406 | -5,921 | -6,406 | 0.00 | 0.04 | - |
| 2013FY | -5,265 | -4,612 | -5,265 | 0.00 | 0.00 | - |
| 2012FY | -6,815 | -4,744 | -6,815 | 0.00 | 0.00 | - |
Quarterly results
2026Q2 revenue 0.00, from 0.00 a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -2.85 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-10-20 | -2.85 | 0.0% |
| 2026Q3 | E | per share | 2026-10-20 | -0.32 | 0.0% |
| 2026FY | R | per share | 2026-10-20 | -2.85 | 0.0% |
| 2026Q3 | R | per share | 2026-10-20 | -0.32 | 0.0% |
| 2026Q3 | S | per share | 2026-09-23 | 0.00 | - |
| 2026Q2 | E | per share | 2026-05-15 | -0.30 | 0.0% |
| 2026Q2 | R | per share | 2026-05-15 | -0.30 | 0.0% |
| 2026Q2 | S | per share | 2026-05-15 | 0.00 | - |
| 2026Q1 | E | per share | 2026-03-30 | -0.28 | -92.3% |
| 2026Q1 | R | per share | 2026-03-30 | -0.28 | -92.3% |
| 2026FY | S | per share | 2026-03-30 | 0.00 | - |
| 2026Q1 | S | per share | 2026-03-30 | 0.00 | - |
| 2025FY | E | per share | 2026-01-21 | -6.10 | -52.3% |
| 2025Q4 | E | per share | 2026-01-21 | -0.62 | -82.4% |
| 2025FY | R | per share | 2026-01-21 | -6.10 | -52.3% |
| 2025Q4 | R | per share | 2026-01-21 | -0.62 | -82.4% |
| 2025Q4 | S | per share | 2026-01-21 | 0.00 | - |
| 2025Q3 | E | per share | 2025-08-12 | -3.27 | 0.0% |
| 2025Q3 | R | per share | 2025-08-12 | -3.27 | 0.0% |
| 2025Q3 | S | per share | 2025-08-12 | 0.00 | - |
| 2025Q2 | E | per share | 2025-08-07 | -3.23 | +23.9% |
| 2025Q2 | R | per share | 2025-08-07 | -3.23 | +23.9% |
| 2025FY | S | per share | 2025-08-07 | 0.00 | - |
| 2025Q2 | S | per share | 2025-05-22 | 0.00 | - |
| 2025Q1 | E | per share | 2025-04-24 | -3.29 | -7.0% |
| 2025Q1 | R | per share | 2025-04-24 | -3.29 | -7.0% |
| 2025Q1 | S | per share | 2025-03-28 | 0.00 | - |
| 2024FY | E | per share | 2025-03-25 | -1.33 | 0.0% |
| 2024Q4 | E | per share | 2025-03-25 | -0.26 | 0.0% |
| 2024FY | R | per share | 2025-03-25 | -1.33 | 0.0% |
| 2024Q4 | R | per share | 2025-03-25 | -0.26 | 0.0% |
| 2024FY | S | per share | 2025-03-25 | 0.00 | - |
| 2024Q4 | S | per share | 2025-03-25 | 0.00 | - |
| 2024Q3 | E | per share | 2024-11-01 | -0.36 | +0.2% |
| 2024Q3 | R | per share | 2024-11-01 | -0.36 | +0.2% |
| 2024Q3 | S | per share | 2024-10-10 | 0.00 | - |
| 2024Q2 | E | per share | 2024-07-24 | -0.40 | 0.0% |
| 2024Q2 | R | per share | 2024-07-24 | -0.40 | 0.0% |
| 2024Q2 | S | per share | 2024-05-10 | 0.00 | - |
| 2024Q1 | E | per share | 2024-03-26 | -0.40 | -0.2% |
| 2024Q1 | R | per share | 2024-03-26 | -0.40 | -0.2% |
| 2024Q1 | S | per share | 2024-03-22 | 0.00 | - |
| 2023FY | E | per share | 2024-03-13 | -1.93 | +0.0% |
| 2023FY | R | per share | 2024-03-13 | -1.93 | +0.0% |
| 2023FY | S | per share | 2024-03-08 | 0.00 | - |
Estimate history
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -941283.245 | -3427.451 | -634.05 | -8000.581 | -97.07 | -40.196 | -24.869 | -19.496 | -6.329 | -4.4849 | - |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Shares million shares | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 3 | 5 | - | 16 |
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -5.518 | -5.318 | -4.084 | -3.159 | -2.069 | -0.791 | -0.816 | -2.534 | -0.345 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares million shares | 2 | 2 | 3 | 4 | 4 | 4 | 5 | 14 | 16 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.25 | 0.27-30.8% | 0.39+2.6% | 0.38-79.0% | 1.81+42.5% | 1.27+56.8% | 0.81-22.9% | 1.05+3400.0% | 0.03 |
| Gross Profit | -0.25 | -0.27 | -0.39 | -0.38 | -1.81 | -1.27 | -0.81 | -1.05 | -0.03 |
| Selling, General and Administrative Excl. Other | 18.21 | 26.31-36.8% | 41.64+44.7% | 28.78-12.3% | 32.83+27.6% | 25.72+39.2% | 18.48-58.3% | 44.35+92.2% | 23.08 |
| Research and Development | 2.87 | 12.39-55.9% | 28.12+60.7% | 17.50-22.3% | 22.53+31.2% | 17.17+19.3% | 14.39-48.3% | 27.84+92.9% | 14.43 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -18.46 | -26.57 | -42.03 | -29.16 | -34.64 | -26.99 | -19.30 | -45.40 | -23.12 |
| Interest Expense | - | 0.21-84.1% | 1.32-9.0% | 1.45-10.5% | 1.62+22.7% | 1.32 | 0.00 | - | 0.13 |
| Unusual Expense | 22.18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 3.72 |
| Net Income Before Taxes | -40.47 | -26.26 | -41.84 | -29.49 | -35.71 | -28.30 | -19.21 | -44.57 | -27.18 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -40.47 | -26.26 | -41.84 | -29.49 | -35.71 | -28.30 | -19.21 | -44.57 | -27.18 |
| Net Income From Continuing Operations | -40.47 | -26.26 | -41.84 | -29.49 | -35.71 | -28.30 | -19.21 | -44.57 | -27.19 |
| Net Income | -40.47 | -26.26 | -41.84 | -29.49 | -35.71 | -28.30 | -19.21 | -44.57 | -27.19 |
| EPS (Recurring) per share | -1.64 | -6.33 | -19.50 | -24.87 | -40.20 | -97.07 | -8,000.58 | -634.05 | -3,099.40 |
| EPS (Basic, Before Extraordinaries) per share | -4.48 | -6.33 | -19.50 | -24.87 | -40.20 | -97.07 | -8,000.58 | -634.05 | -3,427.45 |
| EPS (Diluted) per share | -4.48 | -6.33 | -19.50 | -24.87 | -40.20 | -97.07 | -8,000.58 | -634.05 | -3,427.45 |
| EBITDA | -18.21 | -26.31 | -41.64 | -28.78 | -32.83 | -25.72 | -18.48 | -44.35 | -23.08 |
| Non-Operating Income (Expense) | 0.17 | 0.52-65.3% | 1.50+35.1% | 1.11+101.8% | 0.55 | 0.00-100.0% | 0.09-89.2% | 0.83 | -0.21 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.75 | 3.12-41.1% | 5.30+107.8% | 2.55+63.5% | 1.56+41.8% | 1.10+144.4% | 0.45-89.6% | 4.32+202.1% | 1.43 |
| Shares Outstanding million shares | 15.98 | 4.93+45.9% | 3.38+98.8% | 1.70+109.9% | 0.81+52.8% | 0.53 | 0.00-100.0% | 0.09+28.6% | 0.07 |
| Market Capitalization | 7.66 | 7.66-79.1% | 36.69-41.8% | 63.02+421.3% | 12.09-66.9% | 36.49-10.3% | 40.66-67.0% | 123.12+548.3% | 18.99 |
Income statement, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.06-14.3% | 0.06-14.3% | 0.07+40.0% | 0.07-30.0% | 0.07-53.3% | 0.07-22.2% | 0.05-44.4% | 0.10-80.4% |
| Gross Profit | -0.06 | -0.06 | -0.07 | -0.07 | -0.07 | -0.07 | -0.05 | -0.10 |
| Selling, General and Administrative Excl. Other | 5.19-34.3% | 5.48-49.6% | 4.01-71.1% | 3.53-66.2% | 7.90-16.2% | 10.87+37.8% | 13.87+86.7% | 10.45+71.9% |
| Research and Development | 1.78-53.4% | 0.07-99.1% | 0.49-95.4% | 0.53-92.9% | 3.82-34.6% | 7.57+74.4% | 10.69+155.7% | 7.47+77.0% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -5.25 | -5.54 | -4.08 | -3.60 | -7.97 | -10.94 | -13.92 | -10.55 |
| Interest Expense | 0.00-100.0% | 0.00-100.0% | - | - | 0.05-86.5% | 0.16-56.8% | 0.25-34.2% | 0.33-10.8% |
| Unusual Expense | 0.00 | 22.18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -5.24 | -27.70 | -4.02 | -3.51 | -7.87 | -10.86 | -13.81 | -10.56 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -5.24 | -27.70 | -4.02 | -3.51 | -7.87 | -10.86 | -13.81 | -10.56 |
| Net Income From Continuing Operations | -5.24 | -27.70 | -4.02 | -3.51 | -7.87 | -10.86 | -13.81 | -10.56 |
| Net Income | -5.24 | -27.70 | -4.02 | -3.51 | -7.87 | -10.86 | -13.81 | -10.56 |
| EPS (Recurring) per share | -0.34 | -1.11 | -0.82 | -0.79 | -2.07 | -3.16 | -4.08 | -5.32 |
| EPS (Basic, Before Extraordinaries) per share | -0.34 | -2.53 | -0.82 | -0.79 | -2.07 | -3.16 | -4.08 | -5.32 |
| EPS (Diluted) per share | -0.34 | -2.53 | -0.82 | -0.79 | -2.07 | -3.16 | -4.08 | -5.32 |
| EBITDA | -5.19 | -5.48 | -4.01 | -3.53 | -7.90 | -10.87 | -13.87 | -10.45 |
| Non-Operating Income (Expense) | 0.01-92.9% | 0.02-91.7% | 0.06-82.9% | 0.09-71.9% | 0.14-63.2% | 0.24-45.5% | 0.35-12.5% | 0.32+77.8% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | -0.12-111.0% | 0.23-83.5% | 0.58-56.4% | 0.06-95.5% | 1.09-17.4% | 1.39+5.3% | 1.33+20.9% | 1.33+137.5% |
| Shares Outstanding million shares | 15.98+259.9% | 14.34+307.4% | 4.93+45.9% | 4.44+117.6% | 4.44+136.2% | 3.52+105.8% | 3.38+98.8% | 2.04+85.5% |
| Market Capitalization | 7.66-72.4% | 22.11-34.5% | 14.14-61.5% | 45.64+22.7% | 27.79-42.9% | 33.77-60.8% | 36.69-41.8% | 37.19+871.0% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 | 2017FY12/31/2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 7.71-74.5% | 30.27-22.8% | 39.23+25.6% | 31.23-39.7% | 51.83+175.4% | 18.82-70.4% | 63.51-18.3% | 77.72+341.1% | 17.62 |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.26-79.7% | 1.28-45.1% | 2.33+126.2% | 1.03 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.56-53.7% | 1.21+7.1% | 1.13-34.3% | 1.72-90.0% | 17.13+2214.9% | 0.74-88.3% | 6.34+88.1% | 3.37+212.0% | 1.08 |
| Total Current Assets | 8.27-73.7% | 31.47-22.0% | 40.36+22.5% | 32.95-52.2% | 68.96+247.9% | 19.82-72.1% | 71.13-14.7% | 83.42+322.6% | 19.74 |
| Net Property, Plant & Equipment | 8.14-14.6% | 9.53-11.7% | 10.79-15.1% | 12.71+205.5% | 4.16+39.1% | 2.99-10.2% | 3.33 | 0.00 | 0.00 |
| Total Investments and Advances | 0.390.0% | 0.390.0% | 0.39 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.44 | 0.00 |
| Intangible Assets | - | - | - | - | - | - | - | - | 0.00 |
| Deferred Tax Assets | 2.20-13.4% | 2.54 | - | - | - | - | - | - | - |
| Other Assets | 0.13+30.0% | 0.10+66.7% | 0.06-86.0% | 0.43+290.9% | 0.11+120.0% | 0.05-90.2% | 0.51+142.9% | 0.21+200.0% | 0.07 |
| Total Assets | 19.13-56.5% | 44.02-14.7% | 51.60+12.0% | 46.09-37.1% | 73.24+220.4% | 22.86-69.5% | 74.97-10.8% | 84.07+324.4% | 19.81 |
| Short Term Debt Incl. Current Port. of LT Debt | 1.19-83.5% | 7.22+37.8% | 5.24+271.6% | 1.41-2.1% | 1.44+82.3% | 0.79-59.7% | 1.96+931.6% | 0.19+11.8% | 0.17 |
| Accounts Payable | 1.04-57.6% | 2.45+191.7% | 0.84-24.3% | 1.11+12.1% | 0.99-7.5% | 1.07-28.7% | 1.50-25.0% | 2.00+53.8% | 1.30 |
| Other Current Liabilities | 1.08-76.3% | 4.55+36.6% | 3.33-30.0% | 4.76-72.9% | 17.59+1193.4% | 1.36-85.0% | 9.07+18.9% | 7.63+191.2% | 2.62 |
| Total Current Liabilities | 3.31-76.7% | 14.22+51.1% | 9.41+29.3% | 7.28-63.7% | 20.03+522.0% | 3.22-74.3% | 12.52+27.5% | 9.82+140.1% | 4.09 |
| Long Term Debt | 6.95-14.6% | 8.14-47.2% | 15.42-25.5% | 20.70+21.1% | 17.09+887.9% | 1.73-32.4% | 2.56+573.7% | 0.38-36.7% | 0.60 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 2.20-13.4% | 2.54 | - | - | - | - | - | - | - |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.02-97.3% | 0.75+435.7% | 0.14 |
| Total Liabilities | 12.46-50.0% | 24.90+0.2% | 24.84-11.2% | 27.98-24.6% | 37.12+649.9% | 4.95-67.2% | 15.10+37.9% | 10.95+126.7% | 4.83 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 86.71 | 0.00 | 0.00-100.0% | 132.92 |
| Common Equity | 6.67-65.1% | 19.13-28.5% | 26.77+47.8% | 18.11-49.9% | 36.12 | -68.79-217.5% | 58.55-17.5% | 70.95 | -130.69 |
| Total Shareholders Equity | 6.67-65.1% | 19.13-28.5% | 26.77+47.8% | 18.11-49.9% | 36.12+101.7% | 17.91-69.4% | 58.55-17.5% | 70.95+3081.6% | 2.23 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 1.32-39.2% | 2.17-83.0% | 12.76 |
| Total Equity | 6.67-65.1% | 19.13-28.5% | 26.77+47.8% | 18.11-49.9% | 36.12+101.7% | 17.91-70.1% | 59.87-18.1% | 73.12+388.1% | 14.98 |
| Total Liabilities & Stockholders Equity | 19.13-56.5% | 44.02-14.7% | 51.60+12.0% | 46.09-37.1% | 73.24+220.4% | 22.86-69.5% | 74.97-10.8% | 84.07+324.4% | 19.81 |
| Book Value Per Share per share | 1.35-76.1% | 5.65-64.2% | 15.78-29.5% | 22.38-67.1% | 67.94 | -25,441.92-4170.7% | 625.00-39.7% | 1,035.74 | -538,127.39 |
| Tangible Book Value Per Share per share | 1.35-76.1% | 5.65-64.2% | 15.78-29.5% | 22.38-67.1% | 67.94 | -25,441.92-4170.7% | 625.00-39.7% | 1,035.74 | -538,127.39 |
| Full-Time Employees people | 4-84.0% | 25+47.1% | 17-10.5% | 19+11.8% | 17+30.8% | 13-65.8% | 38+11.8% | 34-5.6% | 36 |
| Price to Book Ratio ratio | -5.62 | 1.92 | -52.96 | 0.45 | 1.01 | 1.23 | 2.10 | 0.42 | 0.69 |
| Return on Assets % | -83.17 | -87.51 | -60.38 | -59.85 | -48.53 | -39.27 | -56.04 | -34.66 | -118.83 |
| Return on Equity % | -203.63 | -182.35 | -131.42 | -131.70 | -81.83 | -50.24 | -68.83 | -40.21 | -153.16 |
| Return on Invested Capital % | -192.86 | -153.45 | -69.90 | -92.01 | -53.19 | -97.80 | -72.93 | -38.12 | -2,991.79 |
| Quick Ratio ratio | 2.50 | 2.21 | 4.29 | 4.53 | 3.44 | 6.15 | 5.68 | 8.50 | 4.82 |
| Current Ratio ratio | 2.50 | 2.21 | 4.29 | 4.53 | 3.44 | 6.15 | 5.68 | 8.50 | 4.82 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -40.47 | -26.26 | -41.84 | -29.49 | -35.71 | -28.30 | -19.21 | -44.57 | -27.18 |
| Depreciation | 0.25 | 0.27-30.8% | 0.39+2.6% | 0.38-79.0% | 1.81+42.5% | 1.27+56.8% | 0.81-22.9% | 1.05+3400.0% | 0.03 |
| Other Funds (Non Cash) | 23.55 | 4.31-36.7% | 6.81+53.7% | 4.43+126.0% | 1.96+16.0% | 1.69+275.6% | 0.45-89.7% | 4.35+76.8% | 2.46 |
| Funds from Operations | -16.67 | -21.69 | -34.64 | -24.68 | -31.94 | -25.34 | -17.95 | -39.17 | -24.68 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -4.06 | -5.13-418.6% | 1.61 | -2.68-408.0% | 0.87 | -0.61 | -1.07 | -2.05-297.1% | 1.04 |
| Cash from Operating Activities | -20.73 | -26.82 | -33.03 | -27.36 | -31.07 | -25.96 | -19.02 | -41.22 | -23.65 |
| Capital Expenditures | 0.00 | 0.00 | -0.43 | -0.17 | -0.56 | -0.14 | -0.05 | -0.40 | -0.04 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.33 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 4.38+75.9% | 2.49 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 4.38+75.9% | 2.49 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.040.0% | 0.04 | 0.00 | 0.00 |
| Cash from Investing Activities | 0.00 | 0.00 | -0.43 | -0.17 | -0.56 | -0.10 | -0.01-100.3% | 3.99+256.3% | 1.12 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 7.23 | 10.69-63.0% | 28.90-18.8% | 35.60+120.6% | 16.14-51.9% | 33.53-3.1% | 34.60+27.5% | 27.14-30.0% | 38.76 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 7.23 | 10.69-63.0% | 28.90-18.8% | 35.60+120.6% | 16.14-51.9% | 33.53-3.1% | 34.60+27.5% | 27.14-30.0% | 38.76 |
| Proceedsfrom Stock Options | 2.67 | 6.09-78.7% | 28.59-19.7% | 35.60+120.6% | 16.14-51.7% | 33.42-3.2% | 34.53+29.5% | 26.67-31.2% | 38.76 |
| Issuance or Reduction of Debt, Net | 0.00 | -6.43 | -4.40 | 0.00 | -4.74-131.8% | 14.90 | 0.00 | -0.20-103.1% | 6.48 |
| Change in Long Term Debt | 0.00 | -6.43 | -4.40 | 0.00 | -4.74-131.8% | 14.90 | 0.00 | -0.20-103.1% | 6.48 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 14.90 | 0.00 | 0.00-100.0% | 6.65 |
| Reduction of Long Term Debt | 0.00 | -6.43 | -4.40 | 0.00 | -4.74 | 0.00 | 0.00 | -0.20 | -0.17 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 10.62 | 0.00 | 0.00-100.0% | 33.32 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -6.42 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 7.23 | 4.26-82.6% | 24.50-31.2% | 35.60+212.3% | 11.40-80.7% | 59.06+70.7% | 34.60+28.4% | 26.94-65.7% | 78.55 |
| Exchange Rate Effect | - | - | - | - | - | - | 0.22+633.3% | 0.03-75.0% | 0.12 |
| Net Change in Cash | -13.50 | -22.56 | -8.96-211.0% | 8.07 | -20.23-161.3% | 33.01+111.9% | 15.58 | -10.26-118.3% | 56.15 |
| Free Cash Flow | -20.73 | -26.82 | -33.46 | -27.53 | -31.63 | -26.09 | -19.07 | -41.62 | -23.68 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 0.78-94.5% | 1.80-91.6% | 7.71-74.5% | 7.51-66.0% | 14.28-54.1% | 21.51-33.5% | 30.27-22.8% | 22.12+98.9% |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.92+12.2% | 0.64-30.4% | 0.56-53.7% | 0.59-59.0% | 0.82+95.2% | 0.92-21.4% | 1.21+7.1% | 1.44+23.1% |
| Total Current Assets | 1.70-88.7% | 2.45-89.1% | 8.27-73.7% | 8.10-65.6% | 15.10-52.1% | 22.43-33.0% | 31.47-22.0% | 23.55+91.6% |
| Net Property, Plant & Equipment | 7.43-16.0% | 7.79-15.2% | 8.14-14.6% | 8.51-13.5% | 8.85-13.0% | 9.19-11.9% | 9.53-11.7% | 9.84-12.9% |
| Total Investments and Advances | 0.390.0% | 0.390.0% | 0.390.0% | 0.390.0% | 0.390.0% | 0.390.0% | 0.390.0% | 0.390.0% |
| Deferred Tax Assets | - | - | 2.20-13.4% | - | - | - | 2.54 | - |
| Other Assets | 0.11-21.4% | 0.12-20.0% | 0.13+30.0% | 0.13+116.7% | 0.14+133.3% | 0.15+150.0% | 0.10+66.7% | 0.06+500.0% |
| Total Assets | 9.63-60.7% | 10.75-66.6% | 19.13-56.5% | 17.13-49.4% | 24.48-41.9% | 32.16-27.5% | 44.02-14.7% | 33.84+41.1% |
| Short Term Debt Incl. Current Port. of LT Debt | 1.29+17.3% | 1.24-76.4% | 1.19-83.5% | 1.15-87.7% | 1.10-88.5% | 5.25-28.3% | 7.22+37.8% | 9.33+187.1% |
| Accounts Payable | 2.00-57.6% | 0.58-73.5% | 1.04-57.6% | 0.92-45.9% | 4.72+247.1% | 2.19+108.6% | 2.45+191.7% | 1.70+49.1% |
| Other Current Liabilities | 1.17-11.4% | 1.49-74.0% | 1.08-76.3% | 1.46-50.3% | 1.32-63.5% | 5.74+147.4% | 4.55+36.6% | 2.94-3.0% |
| Total Current Liabilities | 4.45-37.7% | 3.31-74.9% | 3.31-76.7% | 3.52-74.8% | 7.14-51.0% | 13.18+23.3% | 14.22+51.1% | 13.97+88.3% |
| Long Term Debt | 6.27-17.1% | 6.62-15.7% | 6.95-14.6% | 7.26-13.7% | 7.56-29.1% | 7.85-39.8% | 8.14-47.2% | 8.41-52.6% |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | - | - | 2.20-13.4% | - | - | - | 2.54 | - |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 10.72-27.1% | 9.93-52.8% | 12.46-50.0% | 10.78-51.8% | 14.70-41.7% | 21.03-11.5% | 24.90+0.2% | 22.38-11.1% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | -1.09-111.1% | 0.82-92.6% | 6.67-65.1% | 6.35-44.6% | 9.78-42.3% | 11.13-46.0% | 19.13-28.5% | 11.46 |
| Total Shareholders Equity | -1.09-111.1% | 0.82-92.6% | 6.67-65.1% | 6.35-44.6% | 9.78-42.3% | 11.13-46.0% | 19.13-28.5% | 11.46 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | -1.09-111.1% | 0.82-92.6% | 6.67-65.1% | 6.35-44.6% | 9.78-42.3% | 11.13-46.0% | 19.13-28.5% | 11.46 |
| Total Liabilities & Stockholders Equity | 9.63-60.7% | 10.75-66.6% | 19.13-56.5% | 17.13-49.4% | 24.48-41.9% | 32.16-27.5% | 44.02-14.7% | 33.84+41.1% |
| Book Value Per Share per share | -0.07-103.2% | 0.06-98.1% | 1.35-76.1% | 1.43-74.5% | 2.20-75.6% | 3.16-73.8% | 5.65-64.2% | 5.61 |
| Tangible Book Value Per Share per share | -0.07-103.2% | 0.06-98.1% | 1.35-76.1% | 1.43-74.5% | 2.20-75.6% | 3.16-73.8% | 5.65-64.2% | 5.61 |
| Full-Time Employees people | - | - | 4-84.0% | - | - | - | 25+47.1% | - |
| Price to Book Ratio ratio | -5.62 | 1.21 | 2.01 | 4.66 | 2.15 | 3.03 | 1.92 | 3.25 |
| Return on Assets % | -237.25 | -200.87 | -83.17 | -141.49 | -129.32 | -117.06 | -87.51 | -122.85 |
| Return on Equity % | -931.14 | -721.00 | -203.63 | -405.03 | -322.57 | -282.07 | -182.35 | -691.89 |
| Return on Invested Capital % | -101.18 | -372.41 | -29.53 | -25.81 | -45.38 | -57.20 | -50.66 | -53.14 |
| Quick Ratio ratio | 0.38 | 0.74 | 2.50 | 2.30 | 2.11 | 1.70 | 2.21 | 1.69 |
| Current Ratio ratio | 0.38 | 0.74 | 2.50 | 2.30 | 2.11 | 1.70 | 2.21 | 1.69 |
Cash flow, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -5.24 | -27.70 | -4.02 | -3.51 | -7.87 | -10.86 | -13.81 | -10.56 |
| Depreciation | 0.06-14.3% | 0.06-14.3% | 0.07+40.0% | 0.07-30.0% | 0.07-53.3% | 0.07-22.2% | 0.05 | 0.10-80.4% |
| Other Funds (Non Cash) | 1.89+35.0% | 20.45+1110.1% | 0.87-47.0% | 0.34-79.3% | 1.40-19.1% | 1.69-6.1% | 1.64-42.3% | 1.64+168.9% |
| Funds from Operations | -3.29 | -7.19 | -3.09 | -3.10 | -6.40 | -9.10 | -12.12 | -8.82 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 0.51 | -0.41-138.7% | -0.49-124.7% | -3.67 | -2.03-193.5% | 1.06 | 1.98 | -1.36 |
| Cash from Operating Activities | -2.78 | -7.60 | -3.57 | -6.78 | -8.43 | -8.04 | -10.15 | -10.18 |
| Capital Expenditures | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | -0.01 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | -0.01 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 1.75-67.8% | 1.70+14.9% | 3.77-81.3% | 0.01-99.7% | 5.43+19.1% | 1.48+228.9% | 20.15-41.3% | 3.74+18600.0% |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 1.75-67.8% | 1.70+14.9% | 3.77-81.3% | 0.01-99.7% | 5.43+19.1% | 1.48+228.9% | 20.15-41.3% | 3.74+18600.0% |
| Proceedsfrom Stock Options | 1.75-67.8% | 1.70+18.1% | -0.78-103.9% | 0.00-100.0% | 5.43+19.1% | 1.44+476.0% | 20.15-41.3% | 3.63+18050.0% |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | -4.23 | -2.20 | -2.20 | -2.20 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | -4.23 | -2.20 | -2.20 | -2.20 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | -4.23 | -2.20 | -2.20 | -2.20 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 1.75+45.8% | 1.70 | 3.77-79.0% | 0.01-99.4% | 1.20-73.7% | -0.72-260.0% | 17.95-47.7% | 1.54+7600.0% |
| Net Change in Cash | -1.03 | -5.90 | 0.19-97.6% | -6.77 | -7.23 | -8.76 | 7.80-72.3% | -8.66 |
| Free Cash Flow | -2.78 | -7.60 | -3.57 | -6.78 | -8.43 | -8.04 | -10.15 | -10.20 |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 2.00% | 0.2M | 12.1M | 2.54M |
| 2026-10-15 | 3.07% | 0.3M | 10.2M | 2.55M |
| 2026-09-30 | 5.97% | 0.6M | 10.2M | 2.55M |
| 2026-09-15 | 3.63% | 0.4M | 9.7M | 650.22K |
| 2026-08-31 | 3.95% | 0.4M | 9.7M | 206.72K |
| 2026-08-14 | 3.87% | 0.4M | 9.7M | 195.49K |
| 2026-07-31 | 2.78% | 0.3M | 9.6M | 157.18K |
| 2026-07-15 | 3.31% | 0.3M | 9.6M | 165.81K |
| 2026-06-30 | 2.97% | 0.3M | 9.6M | 195.19K |
| 2026-06-15 | 2.45% | 0.2M | 8.4M | 204.53K |
| 2026-05-29 | 4.07% | 0.3M | 8.4M | 201.39K |
| 2026-05-15 | 4.78% | 0.4M | 8.4M | 202.68K |
| 2026-04-30 | 4.86% | 0.4M | 8.1M | 212.53K |
| 2026-04-15 | 7.88% | 0.6M | 8.1M | 188.61K |
| 2026-03-31 | 5.06% | 0.4M | 8.9M | 144.45K |
| 2026-03-13 | 1.59% | 0.1M | 8.3M | 104.36K |
| 2026-02-27 | 2.04% | 0.2M | 8.3M | 114.90K |
| 2026-02-13 | 2.31% | 0.2M | 8.3M | 155.23K |
| 2026-01-30 | 3.13% | 0.1M | 4.6M | 129.30K |
| 2026-01-15 | 3.27% | 0.2M | 4.6M | 117.77K |
Option chain
Expiry 2026-11-13 · underlying 0.40, quoted 13 Nov 08:12 ET · ATM -
Option quotes -. A date on a row is older than the last session (12 Nov). 0 rows.
Implied move — the ATM straddle is not quoted.
Put/call open interest — no calls · Put/call volume — no calls
IV change is points against the prior close.
| Type | Strike | Money | Bid | Ask | Last | Chg | IV | Open int | Volume | Last size | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | |||||||||||||
Latest SEC filings
30 of 815AllAll annual, quarterly, and current reportsInsider equity awards, transactions, and ownership (Section 16 Reports)Beneficial ownership reportsExempt offeringsRegistration statements and prospectusesFiling review correspondenceSEC orders and noticesProxy materialsTender offers and going private transactionsTrust indenture filings
10-Q filed 2026-08-13, period ended 2026-06-30. 10-K filed 2026-03-30, period ended 2025-12-31. TPST on EDGAR
page 1 of 28Next →
| Filed | Form | Description | Period | Document |
|---|---|---|---|---|
| 2026-11-12 | 8-K | All annual, quarterly, and current reports | 2026-11-11 | 0001213900-26-118986 index |
| 2026-11-10 | 8-K | All annual, quarterly, and current reports | 2026-11-09 | 0001213900-26-118006 index |
| 2026-11-06 | 8-K | All annual, quarterly, and current reports | 2026-11-04 | 0001213900-26-116484 index |
| 2026-11-03 | 3 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-10-26 | 0001213900-26-115343 index |
| 2026-11-02 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-10-13 · transaction | 0001213900-26-114957 index |
| 2026-11-02 | 3 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-10-13 | 0001213900-26-114956 index |
| 2026-11-02 | ARS | Proxy materials | 2025-12-31 | 0001213900-26-114919 index |
| 2026-10-30 | 8-K | All annual, quarterly, and current reports | 2026-10-26 | 0001213900-26-114376 index |
| 2026-10-26 | DEF 14A | Proxy materials | 2026-11-09 | 0001213900-26-112476 index |
| 2026-10-20 | DEFA14A | Proxy materials | no report period | 0001213900-26-111032 index |
| 2026-10-20 | 8-K | All annual, quarterly, and current reports | 2026-10-14 | 0001213900-26-111026 index |
| 2026-10-19 | 8-K | All annual, quarterly, and current reports | 2026-10-13 | 0001213900-26-110669 index |
| 2026-10-16 | PRE 14A | Proxy materials | 2026-11-09 | 0001213900-26-110304 index |
| 2026-10-14 | D | Exempt offerings | no report period | 0001213900-26-109190 index |
| 2026-10-02 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-09-22 · transaction | 0001213900-26-106400 index |
| 2026-10-02 | 3 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-09-22 | 0001213900-26-106399 index |
| 2026-10-02 | 424B3 | Registration statements and prospectuses | no report period | 0001213900-26-106362 index |
| 2026-10-01 | EFFECT | SEC orders and notices | no report period | 9999999995-26-003135 index |
| 2026-09-28 | 8-K | All annual, quarterly, and current reports | 2026-09-22 | 0001213900-26-104034 index |
| 2026-09-25 | S-3 | Registration statements and prospectuses | no report period | 0001213900-26-103526 index |
| 2026-09-17 | 8-K | All annual, quarterly, and current reports | 2026-09-14 | 0001193125-26-394492 index |
| 2026-09-16 | DEFA14A | Proxy materials | no report period | 0001193125-26-393155 index |
| 2026-09-16 | 8-K | All annual, quarterly, and current reports | 2026-09-15 | 0001193125-26-393151 index |
| 2026-09-15 | 8-K | All annual, quarterly, and current reports | 2026-09-11 | 0001193125-26-391903 index |
| 2026-09-01 | 424B3 | Registration statements and prospectuses | no report period | 0001193125-26-378588 index |
| 2026-08-27 | CORRESP | Filing review correspondence | no report period | 0001193125-26-371259 index |
| 2026-08-27 | UPLOAD | Filing review correspondence | no report period | 0000000000-26-008466 index |
| 2026-08-24 | 8-K | All annual, quarterly, and current reports | 2026-08-18 | 0001193125-26-363695 index |
| 2026-08-21 | S-1 | Registration statements and prospectuses | no report period | 0001193125-26-361240 index |
| 2026-08-18 | DEFA14A | Proxy materials | no report period | 0001193125-26-355565 index |
Insider activity
as of 2026-03-24 · 2 filings| Insider | Title | Date | Type | Shares | Value ($) | Price | Remaining | Form 4 |
|---|---|---|---|---|---|---|---|---|
| Angel Matthew | CEO and President | 2026-03-24 | Buy | 231,482 | 500,001 | 2.16 | 231,482 | Jun 23 04:56 PM |
| Angel Matthew | CEO and President | 2026-03-24 | Buy | 231,482 | 500,001 | 2.16 | 231,482 | Mar 25 05:32 PM |
Monthly total
as of 2026-11 · feed totals, not a recount of the rows above| Month | Bought ($) | Buys | Sold ($) | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 1,000,002 | 2 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
as of quote 2026-11-13. 13F filing period is not in this feed — not a live holding. 10 managers, 8.65% of shares, of 5.39% institutional Overlap: Vanguard is on both cards (2 managers, 2 funds). Do not add them.| Manager | % owned |
|---|---|
| SABBY MANAGEMENT, LLC | 3.45% |
| Versant Venture Management, LLC | 1.82% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.58% |
| VANGUARD FIDUCIARY TRUST CO | 0.47% |
| GEODE CAPITAL MANAGEMENT, LLC | 0.44% |
| BlackRock, Inc. | 0.26% |
| Squarepoint Ops LLC | 0.21% |
| UBS Group AG | 0.15% |
| NORTHERN TRUST CORP | 0.14% |
| CITADEL ADVISORS LLC | 0.13% |
Funds
as of quote 2026-11-13. 13F filing period is not in this feed — not a live holding. 7 funds, 1.35% of shares, of 5.39% institutional Overlap: Vanguard is on both cards (2 managers, 2 funds). Do not add them.| Fund | Kind | % owned |
|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND | mutual fund | 0.71% |
| Fidelity Extended Market Index Fund | mutual fund | 0.30% |
| VANGUARD EXTENDED MARKET INDEX FUND | mutual fund | 0.24% |
| Fidelity Total Market Index Fund | mutual fund | 0.05% |
| Dimensional US Core Equity 1 ETF | ETF | 0.03% |
| Fidelity Series Total Market Index Fund | mutual fund | 0.03% |
| Dimensional U.S. Core Equity 2 ETF | ETF | 0.00% |
OakChart. TPST. Cached 15 minutes. Terms